Standout Papers

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II... 2022 2026 2023 2024212
  1. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study (2022)
    Michele Maio, Paolo A. Ascierto et al. Annals of Oncology

Immediate Impact

1 by Nobel laureates 2 from Science/Nature 65 standout
Sub-graph 1 of 21

Citing Papers

Pancreatic cancer
2025 Standout
Digestive cancers: mechanisms, therapeutics and management
2025 Standout
2 intermediate papers

Works of Federico Longo being referenced

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
2022 Standout
Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study.
2021

Author Peers

Author Last Decade Papers Cites
Federico Longo 471 225 216 62 728
Finn Ole Larsen 530 231 234 49 843
Hee Young Na 247 101 138 56 601
Shafei Wu 431 332 156 59 704
Antonio De Leo 210 210 153 95 795
Yulia Kundel 361 200 268 54 765
A Kondi-Pafiti 240 140 248 75 837
Eun Sook Nam 269 126 233 64 749
Masahiro Yamada 333 132 399 55 698
Semen Önder 198 133 188 79 695
Renato Colella 257 280 262 40 833

All Works

Loading papers...

Rankless by CCL
2026